373 related articles for article (PubMed ID: 23633485)
1. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
2. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
4. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT; Sutton CR; Kurupi R; Bialucha CU; Ettenberg SA; Collins SD; Sheng Q; Wallweber J; Defazio-Eli L; Arteaga CL
Cancer Res; 2013 Oct; 73(19):6013-23. PubMed ID: 23918797
[TBL] [Abstract][Full Text] [Related]
5. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
6. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
7. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Meyer DS; Brinkhaus H; Müller U; Müller M; Cardiff RD; Bentires-Alj M
Cancer Res; 2011 Jul; 71(13):4344-51. PubMed ID: 21482677
[TBL] [Abstract][Full Text] [Related]
8. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
Cook RS; Garrett JT; Sánchez V; Stanford JC; Young C; Chakrabarty A; Rinehart C; Zhang Y; Wu Y; Greenberger L; Horak ID; Arteaga CL
Cancer Res; 2011 Jun; 71(11):3941-51. PubMed ID: 21482676
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
[TBL] [Abstract][Full Text] [Related]
10. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
11. Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
Renner O; Blanco-Aparicio C; Grassow M; Cañamero M; Leal JF; Carnero A
Cancer Res; 2008 Dec; 68(23):9643-53. PubMed ID: 19047141
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
[TBL] [Abstract][Full Text] [Related]
13. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
[TBL] [Abstract][Full Text] [Related]
14. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
[TBL] [Abstract][Full Text] [Related]
15. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.
Chakrabarty A; Rexer BN; Wang SE; Cook RS; Engelman JA; Arteaga CL
Oncogene; 2010 Sep; 29(37):5193-203. PubMed ID: 20581867
[TBL] [Abstract][Full Text] [Related]
16. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.
Yuan W; Stawiski E; Janakiraman V; Chan E; Durinck S; Edgar KA; Kljavin NM; Rivers CS; Gnad F; Roose-Girma M; Haverty PM; Fedorowicz G; Heldens S; Soriano RH; Zhang Z; Wallin JJ; Johnson L; Merchant M; Modrusan Z; Stern HM; Seshagiri S
Oncogene; 2013 Jan; 32(3):318-26. PubMed ID: 22370636
[TBL] [Abstract][Full Text] [Related]
17. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
Mancini ML; Lien EC; Toker A
Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
[TBL] [Abstract][Full Text] [Related]
19. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
Korkola JE; Collisson EA; Heiser M; Oates C; Bayani N; Itani S; Esch A; Thompson W; Griffith OL; Wang NJ; Kuo WL; Cooper B; Billig J; Ziyad S; Hung JL; Jakkula L; Feiler H; Lu Y; Mills GB; Spellman PT; Tomlin C; Mukherjee S; Gray JW
PLoS One; 2015; 10(7):e0133219. PubMed ID: 26181325
[TBL] [Abstract][Full Text] [Related]
20. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.
Koren S; Bentires-Alj M
FEBS J; 2013 Jun; 280(12):2758-65. PubMed ID: 23384338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
